Soleno Therapeutics (SLNO) insider updates equity holdings after RSU vest

Rhea-AI Filing Summary

Soleno Therapeutics officer and Senior Vice President of Regulatory Affairs reported an automatic share withholding related to vested restricted stock units (RSUs). On December 15, 2025, 904 shares of common stock were withheld by the company to cover the reporting person’s tax obligations upon RSU settlement at a price of $49.95 per share. After this tax withholding transaction, the insider beneficially owned 12,302 shares of Soleno Therapeutics common stock. Certain of the remaining holdings consist of RSUs, each representing a contingent right to receive one share of common stock, subject to their vesting schedules and conditions.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Hirano Patricia C

Role SEE REMARKS

Type	Security	Shares	Price	Value
Tax Withholding	Common Stock	904	$49.95	$45K

Holdings After Transaction: Common Stock — 12,302 shares (Direct)

Footnotes (1)

1. Represents shares that have been withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the settlement of restricted stock units ("RSUs") which vested on December 15, 2025. Certain of these securities are RSUs. Each RSU represents a contingent right to receive one share of Common Stock, subject to the applicable vesting schedule and conditions of each RSU.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hirano Patricia C

(Last) (First) (Middle)

100 MARINE PARKWAY, SUITE 400

(Street)

REDWOOD CITY CA 94065

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
SOLENO THERAPEUTICS INC [ SLNO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SEE REMARKS

3. Date of Earliest Transaction (Month/Day/Year)
12/15/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	12/15/2025		F(1)		904	D	$49.95	12,302(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares that have been withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the settlement of restricted stock units ("RSUs") which vested on December 15, 2025.

2. Certain of these securities are RSUs. Each RSU represents a contingent right to receive one share of Common Stock, subject to the applicable vesting schedule and conditions of each RSU.

Remarks:

Officer title: Senior Vice President, Regulatory Affairs

	/s/ Anish Bhatnagar, Attorney-in-Fact	12/17/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Soleno Therapeutics (SLNO) report in this Form 4?

The insider reported an automatic tax withholding transaction in which 904 shares of Soleno Therapeutics common stock were withheld on December 15, 2025 in connection with the settlement of vested RSUs.

What role does the reporting person hold at Soleno Therapeutics (SLNO)?

The reporting person is an officer of Soleno Therapeutics with the title Senior Vice President, Regulatory Affairs.

How many Soleno Therapeutics shares were beneficially owned after the reported transaction?

Following the tax withholding transaction, the reporting person beneficially owned 12,302 shares of Soleno Therapeutics common stock.

What price was used for the Soleno Therapeutics shares withheld for taxes?

The 904 shares of common stock withheld to satisfy tax obligations were valued at a price of $49.95 per share.

How are the Soleno Therapeutics RSUs described in this Form 4?

Certain of the reported securities are restricted stock units (RSUs), with each RSU representing a contingent right to receive one share of common stock, subject to applicable vesting schedules and conditions.

Was the Soleno Therapeutics transaction a sale on the open market?

No. The transaction code is F, which here reflects shares withheld by the issuer to satisfy the reporting person’s tax withholding obligations upon RSU vesting, rather than an open-market sale.